RxDoctor Payments Data

Neilay Dedhia

Internal Medicine · Middletown, DENPI 1265052351

Payments from drug & device makers

$1,204in general payments, 2019–2025

Across 72 payments — averaging $16.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$367
  • AbbVie$133
  • Astellas Pharma US Inc$117
  • AstraZeneca$103
  • Lilly USA, LLC$96
  • Pfizer$94
  • plus $295 from 8 others

What the payments were for

  • Food & beverage$1,204100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,204 in reported general payments places this provider in the 80th percentile of 477 internal medicine providers in Delaware.

See all internal medicine providers in Delaware

Medicare billing

Part B allowed, 2024
$198,476
Medicare patients
429
Services billed
2,745

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin131$157,567
MounjaroTirzepatide99$109,673
FarxigaDapagliflozin Propanediol76$82,232
OzempicSemaglutide52$62,050
JanuviaSitagliptin Phosphate42$59,467
EliquisApixaban28$36,420
Trelegy ElliptaFluticasone/Umeclidin/Vilanter32$28,809
TrulicityDulaglutide13$17,555
TradjentaLinagliptin13$12,101
MyrbetriqMirabegron14$9,222
Amlodipine-AtorvastatinAmlodipine/Atorvastatin15$4,053
Atorvastatin Calcium301$3,811
Albuterol Sulfate HfaAlbuterol Sulfate49$2,130
Rosuvastatin Calcium77$1,884
Losartan Potassium189$1,809

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$18$169,667144 claims
Lilly USA, LLCMounjaro, Trulicity$96$127,227112 claims
AstraZenecaFarxiga$103$82,23276 claims
Novo NordiskOzempic$367$62,05052 claims
MerckJanuvia$33$59,46742 claims
PfizerEliquis$94$36,42028 claims
GSKTrelegy Ellipta$61$28,80932 claims
Astellas Pharma US IncMyrbetriq$117$9,22214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 477 internal medicine providers in Delaware.

Other internal medicine in Middletown

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →